Last reviewed · How we verify
RSV prefusion F protein-based vaccine (rsv-prefusion-f-protein-based-vaccine)
Pfizer's RSV prefusion F protein-based vaccine (Arexvy) is a marketed immunization targeting respiratory syncytial virus prevention in adults ≥60 years. The vaccine uses stabilized prefusion F protein technology to elicit robust humoral and cellular immunity against RSV. Clinical trials demonstrated significant efficacy in reducing RSV-associated lower respiratory tract disease in older adults. This represents a first-in-class RSV vaccine for the elderly population, addressing a substantial unmet medical need with high commercial potential. The product has achieved regulatory approval and is generating meaningful revenue in a newly opened vaccine market segment.
At a glance
| Generic name | rsv-prefusion-f-protein-based-vaccine |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Viral protein subunit vaccine |
| Target | Respiratory syncytial virus fusion (F) protein |
| Modality | Vaccine |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older
Common side effects
Drug interactions
- Immunosuppressants
- Anticoagulants
- Corticosteroids
- Antiviral medications
Key clinical trials
- The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products (PHASE4)
- Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults (PHASE4)
- STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)
- Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy
- A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSV prefusion F protein-based vaccine CI brief — competitive landscape report
- RSV prefusion F protein-based vaccine updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI